On November 5, 2025, Avenue Therapeutics, Inc. sold its subsidiary Baergic Bio to Axsome Therapeutics for an upfront payment of $0.3 million and potential additional payments up to $81.5 million based on future milestones and royalties. This deal enables Axsome to develop and commercialize BAER-101 (now AXS-17).